ResMed vs Cardinal Health

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 79)
ResMed logo

ResMed

LeaderHealthcare Tech

Sleep & Respiratory Devices

ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.

AI VisibilityBeta
Overall Score
B76
Category Rank
#71 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
75
Gemini
71

About

ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.

Full profile
Cardinal Health logo

Cardinal Health

LeaderHealthcare Tech

Enterprise

Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.

AI VisibilityBeta
Overall Score
B79
Category Rank
#19 of 596
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
75
Gemini
77

About

Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.

Full profile

AI Visibility Head-to-Head

76
Overall Score
79
#71
Category Rank
#19
83
AI Consensus
90
stable
Trend
stable
72
ChatGPT
79
75
Perplexity
75
71
Gemini
77
77
Claude
77
77
Grok
79

Key Details

Category
Sleep & Respiratory Devices
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only ResMed
Sleep & Respiratory Devices

Integrations

Only Cardinal Health
ResMed is classified as company. Cardinal Health is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.